Purdue Pharma’s chief executive said the company is considering bankruptcy as it faces a cascade of lawsuits alleging that the drugmaker played a key role in driving the nation’s opioid crisis, including aggressively and deceptively marketing the powerful painkiller OxyContin.
Purdue’s president and chief executive, Craig Landau, said in an interview with The Washington Post that the company has not yet decided whether to file bankruptcy, but he said it is something the company is weighing as it considers the impact of potential legal settlements or jury verdicts that could cost tens of billions of dollars.